Studies a blood marker in people with hepatitis B on antiviral treatment
Checks whether HBV pgRNA in blood predicts long-term outcomes in adults with hepatitis B.
Plain-language title generated from the registry record
Registry title: Predictive Value of HBV pgRNA on Long-term Outcomes in Hepatitis B Patients Treated With Antiviral Therapy
Key facts
- Where
- Fuzhou, Hefei, Jinan, Kunming, Nanjing, Shanghai, Taiyuan, Wuhan, Xi’an, and Xuzhou, ChinaSee the 10 sites
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 80 years old?
Source: NCT05965388, who can take part
Where in China
- The First Affiliated Hospital of Fujian Medical UniversityFuzhou, ChinaNo longer taking part
- The First Affiliated Hospital of Anhui Medical UniversityHefei, ChinaNo longer taking part
- Shandong Provincial Hospital of Shandong UniversityJinan, ChinaNo longer taking part
- The First People's Hospital of YunnanKunming, ChinaNo longer taking part
- Jiangsu Province HospitalNanjing, ChinaNo longer taking part
- Huashan HospitalShanghai, ChinaNo longer taking part
- The Third People's Hospital of TaiyuanTaiyuan, ChinaNo longer taking part
- Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyWuhan, ChinaNo longer taking part
- First Affiliated Hospital Xi'an Jiaotong UniversityXi’an, ChinaNo longer taking part
- the Affiliated Hosptial of Xuzhou Medical UniversityXuzhou, ChinaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Wen-hong Zhang
- Trial code
- NCT05965388
- Record updated
- 28 July 2023
- Original description
The goal of this prospective, exploratory, non-intervention, multi-center, real-world study is to investigate the predictive value of HBV pgRNA in the occurrence of long-term outcomes under antiviral therapy in patients with chronic hepatitis B.Read full original descriptionShow less
Predictive Value of HBV pgRNA on Long-term Outcomes in Hepatitis B Patients Treated With Antiviral Therapy
The goal of this prospective, exploratory, non-intervention, multi-center, real-world study is to investigate the predictive value of HBV pgRNA in the occurrence of long-term outcomes under antiviral therapy in patients with chronic hepatitis B.
Participants will take the necessary clinical examination and blood draw during the patient's treatment and follow-up, and all the treatment is determined by clinicians.
Inclusion: CHB defined as positive hepatitis B surface antigen at least 6 months, or HBV-related histological changes within 1 year if HBsAg positive less than 6 months; Age between 18-80 years, gender is not limited；; Patients with chronic hepatitis B who have been determined by clinicians to start, or have already taken the first-line treatment {including pegylated interferon [IFN] monotherapy, a potent nucleos(t)ide analogue [NA] monotherapy, two different potent NAs combination therapy, or NA plus IFN combination therapy; Patient who reads and signs informed consent.
Exclusion: Patients with malignancies other than hepatocellular carcinoma.